Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines

ConclusionThese findings indicated that both the oral vaccine and inactivated vaccine had good safety and immunogenicity in infants aged  ≥ 2 months. The sIPV group generated higher levels of neutralizing antibodies in serum, particularly evident in the post-immunization GMT levels for types II and III.
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research